Aequus Pharmaceuticals Inc. (TSXV:AQS)
Canada flag Canada · Delayed Price · Currency is CAD
0.0050
0.00 (0.00%)
Apr 25, 2025, 8:30 AM EST

Aequus Pharmaceuticals Cash Flow Statement

Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-0.66-2.18-2.96-3.21-1.81-1.05
Upgrade
Depreciation & Amortization
0.170.130.140.130.130.21
Upgrade
Asset Writedown & Restructuring Costs
-0.03-----
Upgrade
Stock-Based Compensation
-0.020.020.050.040.220.3
Upgrade
Other Operating Activities
-0.090.060.070.640.260.25
Upgrade
Change in Accounts Receivable
-0.1-0.030.280.63-0.16-0.22
Upgrade
Change in Inventory
0.090.09-0.030.05-0.02-0.12
Upgrade
Change in Accounts Payable
0.460.330.03-0.090.14-0.1
Upgrade
Change in Other Net Operating Assets
0.06-0.070.14-0.140.07-0.09
Upgrade
Operating Cash Flow
-0.12-1.66-2.29-1.95-1.17-0.8
Upgrade
Capital Expenditures
-----0-0.01
Upgrade
Other Investing Activities
0.040.04----
Upgrade
Investing Cash Flow
0.040.04---0.51-0.01
Upgrade
Short-Term Debt Issued
-1.662.372--
Upgrade
Long-Term Debt Issued
-----0.04
Upgrade
Total Debt Issued
0.11.662.372-0.04
Upgrade
Long-Term Debt Repaid
--0.17-0.16-2.19-0.15-0.14
Upgrade
Net Debt Issued (Repaid)
0.061.492.21-0.19-0.15-0.1
Upgrade
Issuance of Common Stock
----2.552.5
Upgrade
Other Financing Activities
-----0.01-0.34
Upgrade
Financing Cash Flow
0.061.492.21-0.192.42.05
Upgrade
Net Cash Flow
-0.01-0.12-0.08-2.140.721.23
Upgrade
Free Cash Flow
-0.12-1.66-2.29-1.95-1.18-0.82
Upgrade
Free Cash Flow Margin
-12.61%-283.44%-899.97%-141.51%-43.33%-31.52%
Upgrade
Free Cash Flow Per Share
-0.00-0.01-0.02-0.01-0.01-0.01
Upgrade
Cash Interest Paid
--0.010.10.1-
Upgrade
Levered Free Cash Flow
0.24-0.98-1.25-1.11-0.76-0.69
Upgrade
Unlevered Free Cash Flow
0.41-0.82-1.16-1.03-0.63-0.51
Upgrade
Change in Working Capital
0.510.320.420.450.03-0.52
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.